199 related articles for article (PubMed ID: 17140164)
1. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients.
Sirken G; Raja R; Rizkala AR
Clin Nephrol; 2006 Nov; 66(5):348-56. PubMed ID: 17140164
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
3. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
4. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.
Ibrahim HN; Foley RN; Zhang R; Gilbertson DT; Collins AJ
Clin J Am Soc Nephrol; 2009 Mar; 4(3):623-9. PubMed ID: 19211669
[TBL] [Abstract][Full Text] [Related]
5. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
6. The safety of intravenous iron sucrose use in the elderly patient.
Reed J; Charytan C; Yee J
Consult Pharm; 2007 Mar; 22(3):230-8. PubMed ID: 17658969
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
8. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
9. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714
[TBL] [Abstract][Full Text] [Related]
10. Iron sucrose or ferric gluconate?
Duffy CI
Am J Kidney Dis; 2001 Dec; 38(6):1442. PubMed ID: 11728988
[No Abstract] [Full Text] [Related]
11. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
[TBL] [Abstract][Full Text] [Related]
12. Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose.
Guz G; Sahinarslan A; Dhondt AW; Bagdatoglu O; Kavutcu M; Reis KA; Yalçin R; Bali M; Sindel S
Ren Fail; 2004 Nov; 26(6):663-72. PubMed ID: 15600258
[TBL] [Abstract][Full Text] [Related]
13. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
Kaskel FJ
Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
[No Abstract] [Full Text] [Related]
15. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients.
Airy M; Mandayam S; Mitani AA; Chang TI; Ding VY; Brookhart MA; Goldstein BA; Winkelmayer WC
Nephrol Dial Transplant; 2015 Dec; 30(12):2068-75. PubMed ID: 26311216
[TBL] [Abstract][Full Text] [Related]
16. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial.
Garrido-Martín P; Nassar-Mansur MI; de la Llana-Ducrós R; Virgos-Aller TM; Rodríguez Fortunez PM; Ávalos-Pinto R; Jimenez-Sosa A; Martínez-Sanz R
Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):1013-8. PubMed ID: 22940889
[TBL] [Abstract][Full Text] [Related]
17. Do two intravenous iron sucrose preparations have the same efficacy?
Rottembourg J; Kadri A; Leonard E; Dansaert A; Lafuma A
Nephrol Dial Transplant; 2011 Oct; 26(10):3262-7. PubMed ID: 21355067
[TBL] [Abstract][Full Text] [Related]
18. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
19. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
